STAT3 and Hyperglycemia: In leptin-deficient or leptin-resistant HFD models, circulating levels of IL-4 decrease, leading to metabolic abnormalities like obesity, hyperglycemia, IR, liver injury, and changes in AKT, STAT3, and STAT6 pathways.